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.2012.01.0Abstract Lamotrigine is a BCS class II drug with pH dependent solubility. The bilayered gastric
mucoadhesive tablets of lamotrigine were designed such that the drug and controlled release poly-
mers were incorporated in the upper layer and the lower layer had the mucoadhesive polymers. The
major ingredients selected for the upper layer were the drug and control release polymer (either
HPMC K15M or polyox) while the lower MA layer predominantly comprised of Carbopol
974P. A 23 full factorial design was constructed for this study and the tablets were optimized for
parameters like tablet size, shape, ex vivo mucoadhesive properties and unidirectional drug release.opharmaceutical classiﬁcation
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model;
Zero order release;
Unidirectional drug releaseOval tablets with an average size of 14 mm diameter were set optimum. Maximum mucoadhesive
bond strength of 79.3 ± 0.91 * 103 dyn/cm2 was achieved with carbopol when used in combination
with a synergistic resin polymer. All the tested formulations presented a mucoadhesion time of
greater than 12 h. The incorporation of methacrylic polymers in the lower layer ensured unidirec-
tional drug release from the bilayered tablets. The unidirectional drug release was conﬁrmed after
comparing the dissolution results of paddle method with those of a modiﬁed basket method. Model
independent similarity and dissimilarity factor methods were used for the comparison of dissolution
results. Controlled drug release proﬁles with zero order kinetics were obtained with polyox and
HPMC K15M which reported t90% at 6th and 12th hours, respectively. The ‘‘n’’ value with polyox
was 0.992 and that with HPMC K15M was 0.946 indicating an approximate case II transport.
These two formulations showed the potential for oral administration of lamotrigine as bilayered
gastric mucoadhesive tablets by yielding highest similarity factor values, 96.06 and 92.47, respec-
tively, between the paddle and modiﬁed basket method dissolution release proﬁles apart from
reporting the best tablet physical properties and maximum mucoadhesive strength.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Lamotrigine (LM) is an antiepileptic agent used as a mono-
therapy and as an adjunct with other antiepileptic agents for
the treatment of partial seizures andprimary and secondary gen-
eralized tonic–clonic seizures. It is also used for seizures associ-
ated with the Lennox–Gastant syndrome (Brodie, 1992). LM is
a BCS class II drug with pH dependent solubility (solubility in
water is 0.17 mg/mL at 25 C while that in 0.1 M HCl 4.1 mg/
mLat 25 C). LM is an amine containing compoundwith a good
solubility in the acidic or the gastric media and its solubility de-
creases with increasing pH. Gastric retention of such a drug
facilitates better absorption on account of its higher solubility
at stomach’s acidic pH. It is rapidly and completely absorbed
after oral administration with negligible ﬁrst pass metabolism
and requires multiple dosing (2–3 times daily) for maintaining
the therapeutic effect throughout the day. Existing formulations
of LM provide immediate release with tmax ranging from 1.4 to
4.8 h and result into a release proﬁle exhibiting cyclic peaks and
troughs (Cheng et al., 2005). It is also marketed as an extended
release tablet formulation which is manufactured by a special,
laborious and expensive process wherein a central oriﬁce is
drilled into an enteric coated tablet to form a device called Diff-
CORETM (http://www.biospace.com/news_story.aspx?Stor-
yID=169319 &full=1. Date: 2/1/2010, time: 7:08:36 AM). In
order to overcome the limitations of the available formulations,
it was proposed to develop a less laborious, economic and an
industrially applicable method for the delivery of LM with im-
proved solubility and plasma concentrations within the thera-
peutic window over an extended period of time. Therefore, we
consider gastroretentive mucoadhesive formulation of LM as
one of the most attractive routes for the oral delivery of LM.
Bilayered and gastric mucoadhesive drug delivery systems
offer distinct advantages. The phenomenon of bioadhesion is
related to the ability of some synthetic or biologic macromole-
cules and hydrocolloids adhere to biological tissues. If the bio-
logical tissue involved is mucous or mucous membrane, the
phenomenon is referred as mucoadhesion (Joao, 2010).
Mucoadhesion has the potential to localize the drug delivery
by retaining the dosage form at the adhesion site. Gastric
mucoadhesive systems can be the best formulations for the
administration of drugs with good acid solubility and for those
drugs which are rapidly and completely absorbed from gastrointestinal tract (Bardonnet et al., 2006). The concept of bi-layer
tablet was explored in the present study to control the release of
API from one layer by utilizing the functional property of the
other layer since this property ﬁnds appreciation in the fabrica-
tion of novel drug delivery systems (Sivakumar et al., 2010).
This study aimed to develop a gastric mucoadhesive tablet
formulation of LM using Carbopol 974P and polyox as the
mucoadhesive polymers. The primary challenge had been to
handle the incompatibility problem between carbopol and the
amine containing LM (Rowe et al., 2009). Hence, a bilayered
tablet formulation containing drug in one layer and mucoadhe-
sive polymers in the other layer has been worked out so as to
avoid any contact between carbopol and LM. Literature re-
ported the development of several bilayered tablet formulations
for the unidirectional delivery of drugs in the buccal cavity, the
concept of which has been applied in the current research work.
The size of the resting pylorus aperture, 12.8 ± 7 mm was also
considered while designing the tablet size in the present study
(Chanda et al., 2010). The unidirectional and controlled release
of LM for systemic use in the form of bilayered gastric muco-
adhesive tablets (BGMT) was investigated in the present paper.
The aim of present study was to ascertain the feasibility of
in vitro development of BGMT formulation of LM, understand
the effect of different excipients on the ex vivo mucoadhesion
and release proﬁle of ﬁnal formulation besides studying and
exploring the application of a newly designed dissolution meth-
od in combination with model independent methods in charac-
terizing the unidirectional drug release proﬁle.
2. Materials and methods
Lamotrigine (LM), Polyox, HPMC K15M Premium, Carbo-
pol 974P, Eudragit L100, Talc, Aerosil, Magnesium stearate,
Lactose monohydrate and MCC 102 were sponsored by RA
Chem Pharma Ltd. (Hyderabad, India). All chemical reagents
used were of analytical grade. Goat gastric mucosa was ob-
tained from a slaughter house.
2.1. Precompression ﬂow properties and compressibility of
bilayered gastric mucoadhesive tablets
All the precompression properties were determined indepen-
dently for upper ‘‘controlled release (CR) drug layer’’ and
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tapped densities were determined initially with USP tap den-
sity apparatus (Electrolab) from which the Hausner’s ratio
and compressibility index, I (Carr’s index) were further calcu-
lated. The angle of repose was determined by ﬁxed funnel
method.
2.2. Preparation of bilayered gastric mucoadhesive tablets
A 23 full factorial design (FFD) was constructed (Table 1) for
which the composition of mucoadhesive polymer in the lower
mucoadhesive polymer layer, the type and the concentration of
controlled release polymers in the upper controlled release
drug layer were taken as the three independent variables or
factors. The levels of the three factors were selected on the ba-
sis of the preliminary studies carried out before implementing
the experimental design. All other formulation and processing
variables were kept invariant throughout the study. The
dependent variables studied were the bioadhesion force, mean
dissolution time (MDT), difference factor (f1) and similarity
factor (f2).
The two layers of the bilayered tablets were differentiated
as the upper ‘‘controlled release (CR) drug layer’’ and the
lower ‘‘mucoadhesive (MA) polymer layer’’. The tablets were
designed and formulated such that the mucoadhesive polymersTable 1 Selection of independent variables for 23 full factorial desi
Factors (independent variables)
Factor A: Type of control drug release polymer (upper CR layer)
Factor B: Concentration of control drug release polymer (upper CR laye
Factor C: Ratio (Carbopol 974P: Polyox) of primary mucoadhesive poly
(Carbopol 974P) to mucoadhesive synergistic polymer (Polyox) (lower M
a 1 = lower level and +1 = higher level.
Table 2 FFD experimental runs formulae.
S. no. Ingredients 23 FFD runs (L1
L1 L2
Controlled release (CR) layer
1 Lamotriginea 14.3 14.3
2 Lactose monohydrate 11.7 9.7
3 Polyox 13 15
4 HPMC K15M – –
5 MCC 102 7 7
6 Talc 1.5 1.5
7 Aerosil 1.5 1.5
8 Magnesium stearate 1 1
Mucoadhesive (MA) layer
9 Carbopol 974P (RC)b 20 20
10 Eudragit L100 8 8
11 Polyox 20 20
12 Magnesium stearate 2 2
Total tablet weight (mg) 700 700 700
a Dose or tablet strength is 100 mg lamotrigine which approximately co
b RC stands for roller compaction.were accommodated in the lower MA polymer layer while the
drug was incorporated in the upper CR layer. It ensures lack of
interaction between drug and carbopol. The functional muco-
adhesive property of the MA layer was utilized not only to
achieve gastric mucoadhesion but also to modulate the drug
release from the upper CR layer. A total of eight runs were for-
mulated; the formulae for which were presented in Table 2.
Mucoadhesive bilayered tablets were prepared by dry gran-
ulation procedure involving four consecutive steps which in-
clude the slugging and the subsequent compression of each
layer. The compression was manual and the tablets were com-
pressed one after the other. Carbopol 974P was roller com-
pacted (CIP Machineries Pvt. Ltd.) to improve its ﬂow
properties prior to slugging. The entire mucoadhesive polymer
mixture comprising the MA layer was passed through #40,
mixed homogeneously and slugged on a 10 station punching
machine (Rimek karnavathi) using 14.8 * 7.9 mm punches.
The slugs were sieved through #18 and thus obtained MA
layer granules were mixed geometrically with magnesium stea-
rate using a polyethylene bag for 10–15 min to ensure homog-
enous mass. The drug and controlled release polymer mixture
comprising the CR layer was treated in the same way as the
mucoadhesive polymer mixture to obtain CR layer granules.
The mass of MA layer granules equivalent to the MA layer
composition of each individual tablet (350 mg) was com-gn (FFD).
Levelsa
1 +1
Polyox HPMC K15M
r) (%) 13 15
mer
A layer)
50:50 75:25
–L8) showing % w/w of ingredients used
L3 L4 L5 L6 L7 L8
14.3 14.3 14.3 14.3 14.3 14.3
11.7 9.7 11.7 9.7 11.7 9.7
– – 13 15 – –
13 15 – – 13 15
7 7 7 7 7 7
1.5 1.5 1.5 1.5 1.5 1.5
1.5 1.5 1.5 1.5 1.5 1.5
1 1 1 1 1 1
20 20 30 30 30 30
8 8 8 8 8 8
20 20 10 10 10 10
2 2 2 2 2 2
700 700 700 700 700
nstitutes 14.3% of the total tablet weight (700 mg).
48 K. Mohana Raghava Srivalli et al.pressed for a period of half the consolidation time and a loose
compact was formed. The upper punch was raised and the
slugged CR layer granules (350 mg) were then added on the
MA layer compact and the two layers were compressed to
form a ﬁnal bilayered tablet (700 mg).
2.3. Evaluation of bilayered gastric mucoadhesive tablets
2.3.1. In process tests
Weight variation test, tablet thickness, hardness, friability, dia-
metrical fracture (DF)1, and CSFR (Crushing Strength: Fria-
bility ratio)1 (Sivakumar et al., 2010) were reported for all
the formulations. Tablets were evaluated for uniformity in
weight using an electronic balance (Sartorius). The thickness
and hardness were measured using an electronic hardness tes-
ter (Pharmag Tab test) and friability was measured using
Roche-type friabilator (Electrolab Pvt. Ltd., India). DF was
visually examined and CSFR was calculated from the hardness
and friability values.
2.3.2. Measurement of bioadhesion
The ex vivo adhesion studies were conducted using a modiﬁca-
tion of test assembly described by Gupta et al. (1992) and Patel
et al. (2007). The goat stomach mucosa was kept frozen in pH
1.2 acid buffer and thawed to room temperature before use.
The membrane was excised by removing the underlying con-
nective and adipose tissues and was equilibrated at
37 ± 0.5 C for 30 min in pH 1.2 acid buffer before the study.
The upper CR layer of the tablet was glued to the apparatus
assembly while the lower MA layer was exposed to the muco-
sal surface. The tablet was placed on mucosa under constant
weight of 5 g for a total contact period of 1 min. The bioadhe-
sive strength was determined by measuring the strength re-
quired for complete breakdown of bioadhesive bond between
the dosage form and the surface of mucosa. Each measurement
was carried out in triplicate and the results were averaged. The
peak force of detachment was calculated for each bioadhesive
strength value and ﬁnally the corresponding mucoadhesive
bond strength was further calculated and reported for each
batch.
2.3.3. Ex vivo mucoadhesion time
The ex vivo mucoadhesion time was examined (n= 3) after
adhering the gastric mucoadhesive tablet on freshly cut goat’s
gastric mucosa (Han et al., 1999; Patel et al., 2007; Raval and
Patel, 2011). Goat’s fresh gastric mucosa was pasted on the
glass slide using a cyanoacrylate adhesive, and the mucoadhe-
sive core side (MA layer) of tablet was wetted with a drop of
pH 1.2 acid buffer and adhered to goat’s gastric mucosa by
applying a light force with ﬁngertip for 30 s. The glass slide
was then placed in a beaker, which was ﬁlled with 200 mL of
the pH 1.2 acid buffer and kept at 37 C± 0.5 C. After
2 min, a slow stirring rate (50 rpm) was applied to simulate
the gastric environment, and the tablet mucoadhesion was
monitored for 12 h. The time for the tablet to detach from
goat’s gastric mucosa was recorded as the mucoadhesion time.
2.3.4. Assay and in vitro drug release studies
Ten tablets were weighed and powdered using a mortar and
pestle. Powder equivalent to the quantitative mass of onetablet (equivalent to 100 mg of LM) was transferred into a vol-
umetric ﬂask containing 0.1 N HCl. Following sonication, the
sample was ﬁltered (Whatmann ﬁlter paper, 0.2 lm), suitably
diluted and analyzed spectrophotometrically (ELICO-SL 164
double beam spectrophotometer, Hyderabad, India) at kmax
of LM at 244 nm. For each batch, the assay procedure was
performed in triplicate and the average was recorded. In vitro
drug release studies were performed on the tablet matrices of
all the batch formulations using the USP apparatus II (Elec-
trolab TDT-08L, India) with 900 mL of 0.1 N HCl as the med-
ium at 37 ± 0.5 C and 50 rpm rotation rate. At the end of
predetermined time intervals (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11 and 12 h), aliquots (5 mL) were withdrawn from each disso-
lution vessel and replaced with an equal volume of drug free
medium (5 mL). The samples were ﬁltered and analyzed by
ultraviolet spectroscopy at 244 nm with a total of six replicate
determinations for each batch to quantify the percentage drug
released at each time point. Release kinetics for all the eight
batch formulations of 23 FFD runs were studied using Micro-
soft Ofﬁce Excel 2007 version. The release data was analyzed
by ﬁtting the drug release proﬁles into zero order, ﬁrst order,
Higuchi and Korsmeyer Peppas models. Correlation coefﬁ-
cients (r2) and rate constants were calculated for each of the
models. Further, the release mechanism and the MDT were
studied from the power law Peppas model.
2.3.5. Modiﬁed basket method
The in vitro drug release studies of bilayered tablets were fur-
ther carried out using the USP dissolution apparatus I (Elec-
trolab TDT-08L, India). In order to mimic the in vivo
adhesion of the devises (Narendra et al., 2005), the lower
MA layer of the bilayered tablet was attached through cyano-
acryl adhesive to the bottom end of the stirring rod instead of
placing the tablet in the basket ﬁxtures. By this, only drug con-
taining upper CR layer was exposed to the dissolution med-
ium. The rotation rate was 100 rpm and 900 mL of freshly
prepared 0.1 N HCl was used as dissolution medium main-
tained at 37 ± 0.5 C. At predetermined time intervals samples
were withdrawn for UV analysis at 244 nm. The dissolution
studies of all the batch formulations were performed in six
replicates.
2.3.6. Model independent analysis for the characterization of
unidirectional drug release
The dissolution results of the modiﬁed basket method were set
as reference and the results of the paddle method were consid-
ered as the test sample. For each dissolution run, a mean of six
determinations was recorded for the reference and test meth-
ods both of which were matched for similarity in drug release
proﬁles by calculating the similarity and difference factors. A
comparison of the similarity and difference factors was
obtained.
The similarity factor (f2) was calculated as
f2 ¼ 50  log 1þ ð1=nÞ
Xn
t¼1
 ðRt  TtÞ2
" #0:5
 100
8<
:
9=
;
The difference factor (f1) was calculated as
f1 ¼
Xn
t¼1
jRt  Ttj
#" ,Xn
t¼1
 ½Rt
( )
 100
Figure 1 Comparison of the Crushing Strength: Friability Ratio
of all the 23 FFD experimental runs as mean ± SD, n= 3.
Design of a novel bilayered gastric mucoadhesive system 49Rt and Tt are the cumulative percentage dissolved at each of
the selected ‘‘n’’ time points of the reference and test product,
respectively.
3. Results and discussions
3.1. Formulation of bilayered gastric mucoadhesive tablets
The current work was undertaken to formulate bilayered gas-
tric mucoadhesive tablets (BGMT) of lamotrigine (LM) by dry
granulation method and to perform the in vitro evaluation of
the formulation. The aim was to conﬁrm the two layers of
the bilayered tablet functioned independently such that the
MA layer of the tablet which was designed to adhere to the
gastric mucosa posses’ good bioadhesive strength and CR
layer controls the drug release unidirectionally. The dependent
variables studied for the 23 FFD runs namely the bioadhesion
force, MDT, f1 and f2 were reported in Table 3.
3.2. Tablet physical properties and characterization
The major excipients selected for the upper CR layer were the
drug and control release polymer (either HPMC K15M or
polyox). The lower MA layer predominantly comprised Car-
bopol 974P, polyox and Eudragit L100. The precompression
ﬂow properties were studied separately for the upper CR layer
and the lower MA layer. Roller compaction solved the poor
ﬂow of Carbopol 974P. Slugging excellently improved the ﬂow
properties of both the layers. Flow properties were further im-
proved by the addition of silica and the lubricant, magnesium
stearate which was added prior to tableting (He et al., 2007).
Angle of repose values of the upper CR layer ranged between
25 and 28 while that of the lower MA layer ranged between
22 and 27. The compressibility index values of the formula-
tion batches ranged between 8% and 13% for both the upper
CR layer and the lower MA layer indicating the suitability of
the powders for dry granulation. Hausner’s ratio ranged be-
tween 1 and 1.2 for both the layers.
The addition of different polymers did not affect the tablet
physical characteristics. All tablet formulations presented
hardness in the range 9–11 kg/cm2 and passed the diametrical
fracture test. The percent friability values reported for the tab-
let formulations were very low (<0.12%) with no measurable
differences among the between batch results. The CSFR
(Crushing Strength: Friability Ratio) of all the batches wasTable 3 Dependent variables.
FFD runs Mucoadhesive bond strength*103 dyn/cm2
L1 78.2
L2 79.3
L3 78.6
L4 77.9
L5 70.2
L6 73.4
L7 71.2
L8 72.8
a Similarity and difference factors (f1 and f2) for 2
3 FFD runs were ca
method with their corresponding modiﬁed basket reference method resul
b Mean dissolution time.>90 indicating appreciable mechanical strength of the bilay-
ered tablets (Fig. 1). The thickness ranged between
7.11 ± 0.01 mm and 7.18 ± 0.01 mm while the weight of dif-
ferent batch formulations varied between 700 ± 0.82 mg and
700 ± 0.94 mg.
3.3. Effect of formulation variables on bioadhesion force
Carbopol 974P and polyox were used to form the bioadhesive
polymer mixture in the lower MA layer. The mucoadhesive ef-
fect was studied by varying the ratio of Carbopol 974P to poly-
ox as 50:50 and 75:25. The preliminary trails showed that the
bioadhesion of the BGMT increases signiﬁcantly with increase
in carbopol concentration. Higher concentrations of carbopol
upon exposure to the moist surfaces lowered the pH of the
microenvironment which caused an increase in bioadhesion.
The acidic environment favors the presence of excess un-
charged COOH groups which form stronger hydrogen bonds
with water and strengthen the mucoadhesive bond (Park and
Robinson, 1987; Ponchel et al., 1987). The 50:50 ratio of Car-
bopol 974P to polyox was set as optimal formulation as it re-
corded the highest mucoadhesive bond strength (Table 3).
Such a behavior may be attributed to the synergistic mucoad-
hesive effect of polox and Carbopol 974P. The formulations
had not detached from the mucosa through out the observa-
tion period of 12 h thus promising a residence period of not
less than 12 h.MDT (h)b f1
a f2
a
3.348625 3.027494594 84.61878888
4.350583 1.79981203 91.34875888
5.562674 2.833691616 86.9944641
6.197267 2.659747 85.14939911
3.313689 1.811824539 90.44206798
4.07946 4.393823437 76.31060377
5.511291 2.093023256 89.1357774
6.00934 5.169628433 73.96518287
lculated by comparing the dissolution proﬁles derived from paddle
ts.
Figure 2 Comparison of drug release proﬁles modulated by the optimized percentages of controlled release polymers, 13% polyox (L1)
and 15% HPMC K15M (L4) as mean ± SD, n= 6.
50 K. Mohana Raghava Srivalli et al.3.4. In vitro drug release proﬁle
In addition to mucoadhesivity, controlled drug release was
also a prerequisite for this formulation. The formulations were
subjected to in vitro dissolution testing to study their drug re-
lease proﬁle. A formulation with an appropriate controlled re-
lease proﬁle and 90% drug release over a 6–12 h period was
desired for the purpose of this study. Since preliminary studies
conﬁrmed that the polymers polyox and HPMC K15M had
not presented any problem of burst drug release, an attempt
was made to study the drug release modulation by these poly-
mers at 13% and 15% concentrations.
It was evident from the dissolution proﬁles that while the
drug release rate was controlled, 90% of LM was released with
13% polyox (L1 and L5) and 15% HPMC K15M (L4 and L8)
by the end of 6 and 12 h, respectively. Polyox at both 13% and
15% concentrations retarded the drug release for a lesser dura-
tion compared to HPMC K15M which could be due to the dif-
ference in their viscosities. The extended retardation of drug
release observed with HPMC K15M may be attributed to
the three dimensional gel network structure developed by com-
plex formation between the drug and the polymer following
penetration of dissolution medium into the tablet matrix. Poly-
ox being a water soluble resin, might have altered the struc-
tural properties of the tablet matrix by creating an increased
porosity, thus allowing more rapid penetration of the dissolu-
tion medium into the tablet which in turn facilitated the fasterTable 4 Model dependent kinetic analysis of the dissolution proﬁle
FFD runs Zero order release
model parameters
First order release
model parameters
Higuchi rele
parameters
r2 K0 r
2 K1 r
2
L1 0.999 14.96 0.908 0.713 0.98
L2 0.997 12.82 0.951 0.597 0.985
L3 0.999 9.29 0.948 0.526 0.986
L4 0.999 8.2 0.852 0.46 0.976
L5 0.999 15.33 0.906 0.709 0.981
L6 0.985 12.86 0.973 0.59 0.981
L7 0.999 9.69 0.935 0.523 0.982
L8 0.999 8.6 0.808 0.45 0.976drug release behavior. Fifteen percent polyox and thirteen per-
cent HPMC K15M presented an unusual drug release block-
ade after 80% drug release indicating that these percentages
are inappropriate for the complete release of LM from the
BGMT formulation. Therefore, for the purpose of this study,
formulation with 13% polyox or 15% HPMC K15M in the
upper CR layer was considered most suitable. Hence, the for-
mulations comprising of 13% polyox or 15% HPMC K15M in
the upper CR layer and 50:50 ratio of Carbopol 974P to poly-
ox in the lower MA layer were identiﬁed as being capable of
providing both optimum mucoadhesion and a controlled drug
release proﬁle. Fig. 2 depicts the graphical representation of
drug release proﬁles modulated by the optimized percentages
of controlled release polymers, 13% polyox (L1) and 15%
HPMC K15M (L4).
3.5. Characterization of the optimal formulation
The formulations were further subjected to a detailed charac-
terization in terms of release kinetics. The study results were
presented in Table 4.
3.5.1. Kinetic analysis of drug release proﬁles and model ﬁtting
The evaluation of the drug release proﬁle kinetics of all the 23
FFD experimental runs was based on the correlation coefﬁ-
cient (r2) values. The results depicted that all the release pro-
ﬁles best ﬁtted into the zero order kinetic model (indicateds of 23 FFD runs.
ase model Korsmeyer–Peppas
release model parameters
Release mechanism
KH r
2 KKP n
26.98 0.999 0.151 0.992 Case II transport
24.8 0.994 0.178 0.743 Anomalous transport
20.53 0.999 0.104 0.924 Anomalous transport
19.76 0.999 0.09 0.946 Case II transport
27.53 0.999 0.158 0.967 Case II transport
25.47 0.989 0.155 0.855 Anomalous transport
21.14 0.997 0.118 0.863 Anomalous transport
20.56 0.999 0.099 0.913 Anomalous transport
Design of a novel bilayered gastric mucoadhesive system 51by the highest r2 values) which signiﬁed that all the formula-
tions by kinetics followed zero order.
3.5.2. Release mechanism
In order to understand the complex mechanism of drug release
from the BGMT, the in vitro LM release data were studied
using Korsmeyer Peppas release model. The release exponent
(n) values from the power law Peppas equation enlightens in
understanding the release mechanism from the dosage form.
The n values thus obtained ranged from 0.74 to 0.99. Formu-
lations L2, L3, L6, L7, and L8 exhibited anomalous (non-Fic-
kian transport) diffusion mechanism with n value ranging
between 0.74 and 0.92 (Table 4). The anomalous transport re-
fers to a combination of diffusion and erosion controlled drug
release from the polymer and it occurs due to the coupling of
Fickian diffusion and case II transport. This means while the
erosion did occur to some extent, the mechanism of drug re-
lease was not purely erosion dominant. The n values suggested
that the mechanism of drug release was anomalous and was
controlled by a combination of diffusion, polymeric relaxation
and erosion. For formulations L1, L4, and L5, the release
exponent values were observed between 0.95 and 0.99 conﬁrm-
ing the closeness to the attainment of an ideal zero order drug
release. The n values (Table 4), indicated the release mecha-
nism of LM from these BGMT as an approximate case II
transport, where the drug release is due to polymer dissolution
and erosion. Case II generally refers to the erosion of the poly-
meric chain after swelling where the matrix relaxation holds a
predominant role to play. The drug is released as the polymer
swells, relaxes and erodes gradually. The zero order drug re-
lease behavior here may suggest that the release of LM was
controlled by a combination of polymer matrix erosion and
the three dimensional network structure which was produced
by polymer complex formation following liquid penetration
into the tablet (Peppas, 1985). Hence the results signiﬁed that
polyox at 13% and HPMC K15M at 15% concentrations pre-
dominantly modulated the drug release in a controlled fash-
ion. Since these formulations reported highest r2 values for
zero order kinetic model, it was remarked that the LM release
from these BGMT not only followed zero order kinetics but
also zero order controlled release mechanism. Therefore the
runs L1 and L4 were considered as optimal formulations on
account of their reproducible and promising drug release
proﬁles.
3.5.3. Mean dissolution time
Mean dissolution time (MDT) value is generally used to char-
acterize the drug release rate from a dosage form and it indi-
cates the drug release retarding efﬁciency of a polymer. The
results showed that the MDT values were approximately con-
stant for a given controlled release polymer at a given concen-
tration irrespective of the lower MA layer composition
(Table 3). The MDT values of Run L1  Run L5, similarly
that of Run L2  Run L6, Run L3  Run L7 and Run
L4  Run L8. This indicates that the lower MA layer compo-
sition does not interfere with the drug release modulation facil-
itated by the upper CR layer. The drug release retarding
efﬁciency of polymers was in the order polyox 13%< polyox
15%<HPMC K15M 13%<HPMC K15M 15%. This ﬁnd-
ing can be related to the ascending order of polymer viscosities
(Mockel and Lippold, 1993).3.6. Unidirectional drug release studies
3.6.1. In vitro release studies by modiﬁed basket method
The in vitro drug release studies of gastric mucoadhesive com-
pacts were additionally carried out using the USP dissolution
apparatus I. By this modiﬁed basket method design, only the
peripheral/upper CR drug layer of the gastric mucoadhesive
compact was exposed to the dissolution medium which ensures
the study of in vitro unidirectional drug release. All the tablet
batches run were incorporated with a rigidizing polymer,
Eudragit L100 in the lower mucoadhesive layer. This ingredi-
ent is insoluble in gastric pH and hence expected to prevent
any deformation of tablet all through the course of its gastric
residence time. The purpose was served as none of the tablets
showed deformation during the in vitro dissolution studies car-
ried out by both the paddle method and modiﬁed basket
method.
3.6.2. Characterization of unidirectional drug release
Model independent methods (similarity factor, f2 and differ-
ence factor, f1) were used for the characterization and optimi-
zation of 23 FFD experimental runs with respect to their
unidirectional release proﬁle. The dissolution results of the
modiﬁed basket method were set as reference and the results
of the paddle method were considered as the test sample.
The similarity factor denoted as f2 directly compares the simi-
larity in the percentage drug dissolved per unit time between
the test and reference products. The f2 is a logarithmic trans-
formation of the sum squared error of differences between
the test and reference products over all time points (Thomas
et al., 1998; Costa and Jose, 2001; Costa, 2001; Ruben et al.,
2008). The comparison of the similarity and difference factors
obtained for all the eight formulations was presented in Ta-
ble 3. The tabulated values signiﬁed that the paddle method
dissolution proﬁles of all the formulations showed signiﬁcant
similarity with their respective modiﬁed basket method disso-
lution proﬁles. In general, f2 values higher than 50 (50–100)
signiﬁes similarity of the dissolution proﬁles. The 23 FFD for-
mulation runs L1, L2, L4 and L5 showed exceptionally high
(>90) f2 values. The formulations, L1 with polyox 13% and
L4 with 15% HPMC K15M were optimized attributing to
their highest f2 values. Higher similarity factor implies predom-
inant and ensured unidirectional drug release.
Based on the results obtained from various tests namely
precompression analyses, tablet physical tests, ex vivomucoad-
hesion studies, dissolution studies and unidirectional drug re-
lease studies, the precise polymeric combinations comprising
of 13% polyox or 15% HPMC K15M in the upper CR layer
and 50:50 ratio of Carbopol 974P to polyox in the lower
MA layer were identiﬁed as the most potent formulations pro-
viding both enhanced mucoadhesion and unidirectional con-
trolled drug release.
4. Conclusion
The results signiﬁed that the in vitro development of bilayered
gastric mucoadhesive tablets with optimal mucoadhesion and
ensured unidirectional controlled drug release proﬁle for lam-
otrigine was feasible. The study of drug release kinetics and the
mechanism indicated zero order drug release from the
52 K. Mohana Raghava Srivalli et al.optimized formulations. While the combined use of polyox
and Carbopol 974P demonstrated maximum mucoadhesive
strength, the addition of Eudrgit L100 ensured unidirectional
drug release proﬁle. The newly designed modiﬁed basket disso-
lution method in combination with model independent meth-
ods proved successful in characterizing the unidirectional
drug release proﬁle from the formulation. Therefore, for a
drug like lamotrigine, a BCS class II drug with pH dependent
solubility and incompatibility with the most promising muco-
adhesive polymer, carbopol, a novel bilayered gastric mucoad-
hesive tablet may serve as the best possible rationale, potential,
economic and industrially applicable formulation for the deliv-
ery of lamotrigine for an extended period of time from 6 to
12 h.
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